Want to see VMD full AI Analyst Report?
Viemed Healthcare (VMD) AI Stock Analysis
Viemed Healthcare
(NASDAQ:VMD)
Viemed Healthcare earns a strong score driven primarily by its record-breaking revenue growth, virtually debt-free balance sheet, and raised guidance. The recent third-quarter report is a significant positive catalyst, showcasing expanding margins that alleviate earlier profitability concerns. Bullish technical indicators further support the stock's momentum. The main constraint is its moderate P/E valuation and lack of a dividend, but this is heavily offset by aggressive share repurchases and healthy cash flow generation, making it a compelling growth opportunity with low financial risk.
Viemed Healthcare (VMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $385.07M
- Dividend Yield
- ―
- Average Volume (3M)
- 304.38K
- Price to Earnings (P/E)
- 24.8
- Beta (1Y)
- 0.48
- Revenue Growth
- 25.21%
- EPS Growth
- 6.14%
- Country
- US
- Employees
- 1,438
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Viemed Healthcare Business Overview & Revenue Model
Company Description
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chroni...
How the Company Makes Money
Viemed primarily makes money by providing home-based respiratory therapy solutions that combine durable medical equipment (DME) with ongoing clinical and support services, and then billing third-party payors for those products and services. Its core...
Viemed Healthcare Earnings Call Summary
The call presented multiple material operational and financial positives: record revenue, the largest-ever active ventilator patient base, strong sequential and year-over-year growth in sleep and resupply, improving compliance, improved cash generation, and clear investments in technology and scalability (e.g., Tenor). Offsetting these were margin pressures in adjusted EBITDA and gross margin driven by revenue mix shifts, temporary maternal health transition costs, higher SG&A from deliberate scaling and one-time duplicative costs, and some near-term uncertainty on RT capacity. Management communicated confidence in the growth trajectory, provided constructive explanations for margin dynamics, and raised revenue guidance while outlining levers for second-half operating leverage.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised full‑year 2026 revenue guidance to $314–$320 million (from $312–$320M), narrowed adjusted EBITDA to $64–$68 million (from $65–$69M), and lowered net CapEx guidance to 8.5–10.0% of revenue (from 9–10.5%), while calling for continued sequential growth through H2 and an adjusted EBITDA margin of at least 20%; they emphasized generating solid free cash flow (H1 FCF $11.2M, trailing‑12M FCF $34.4M), funding ongoing growth, and preserving balance‑sheet flexibility after repaying about $2.2M of debt, repurchasing ~531,000 shares for $5.1M and ending June with $10.7M in cash (more cash than total debt).
Viemed Healthcare Financial Statement Overview
Summary
Viemed presents a highly robust financial profile characterized by sustained double-digit revenue expansion and an incredibly conservative, virtually debt-free balance sheet. While there has been slight historical margin compression, accelerating operating cash flows and strong liquidity heavily outweigh these minor weaknesses.
Income Statement
82Very PositiveBalance Sheet
88Very PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 301.61M | 270.28M | 224.26M | 183.01M | 138.83M | 117.06M |
| Gross Profit | 172.55M | 155.46M | 133.20M | 112.78M | 84.68M | 73.41M |
| EBITDA | 53.62M | 51.56M | 42.31M | 36.68M | 24.82M | 24.13M |
| Net Income | 14.50M | 14.93M | 11.27M | 10.24M | 6.22M | 9.13M |
Balance Sheet | ||||||
| Total Assets | 204.22M | 214.94M | 177.07M | 154.90M | 117.04M | 117.96M |
| Cash, Cash Equivalents and Short-Term Investments | 10.68M | 13.50M | 17.54M | 12.84M | 16.91M | 28.41M |
| Total Debt | 11.60M | 15.95M | 6.87M | 10.32M | 694.00K | 6.52M |
| Total Liabilities | 58.26M | 71.42M | 43.77M | 41.00M | 19.95M | 23.14M |
| Stockholders Equity | 144.03M | 141.54M | 131.39M | 113.89M | 97.09M | 94.82M |
Cash Flow | ||||||
| Free Cash Flow | 29.24M | 11.93M | 1.32M | 19.12M | 4.85M | 2.75M |
| Operating Cash Flow | 60.78M | 51.92M | 39.09M | 45.21M | 27.75M | 22.49M |
| Investing Cash Flow | -53.23M | -50.17M | -30.70M | -52.11M | -23.98M | -19.75M |
| Financing Cash Flow | -16.89M | -5.79M | -3.69M | 2.83M | -15.27M | -5.32M |
Viemed Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VMD, the sentiment is Positive. The current price of 10.11 is above the 20-day moving average (MA) of 9.70, above the 50-day MA of 9.26, and above the 200-day MA of 9.60, indicating a bullish trend. The MACD of 0.13 indicates Positive momentum. The RSI at 62.31 is Neutral, neither overbought nor oversold. The STOCH value of 37.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VMD.
Viemed Healthcare Risk Analysis
Viemed Healthcare disclosed 39 risk factors in its most recent earnings report. Viemed Healthcare reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksViemed Healthcare Peers Comparison
Overall Rating
- VMD81Outperform
TCMD75Outperform
BVS66Neutral
OM54Neutral
INGN48Neutral
SENS43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VMD | 81Outperform | $360.12M | 24.83 | 10.30% | ― | 25.21% | 6.14% |
| TCMD | 75Outperform | $555.11M | 25.89 | 10.73% | ― | 14.41% | 34.35% |
| BVS | 66Neutral | $922.24M | 13.49 | 27.23% | ― | 3.87% | 623.68% |
| OM | 54Neutral | $77.92M | -1.15 | -62.25% | ― | -1.26% | 79.82% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INGN | 48Neutral | $186.30M | -8.02 | -13.17% | ― | 3.15% | 14.61% |
| SENS | 43Neutral | $468.46M | -3.97 | -165.83% | ― | 90.63% | -11.42% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VMD | Viemed Healthcare US | 10.11 | 3.85 | 61.50% | |
| INGN | Inogen Inc | 7.22 | 0.19 | 2.70% | |
| SENS | Senseonics Holdings Inc. | 9.02 | 2.80 | 45.02% | |
| TCMD | Tactile Systems Technology | 27.18 | 3.31 | 13.87% | |
| OM | Outset Medical, Inc. | 4.44 | -7.37 | -62.40% | |
| BVS | Bioventus, Inc. | 11.42 | 3.94 | 52.67% |
Viemed Healthcare Corporate Events
Viemed Reports Record Third-Quarter Revenue and Profit Growth
PositiveOn November 4, 2026, Viemed reported record third-quarter net revenue of $80.7 million, up 12.2% year over year and 3.3% sequentially. Net income attributable to Viemed rose 32.0% year over year to $4.6 million, while Adjusted EBITDA increased 5.8% t...
Viemed Healthcare Updates Investor Deck, Highlights Growth Strategy
PositiveViemed Healthcare has released an updated investor deck dated August 2026, which it plans to use in presentations to investors, analysts and other stakeholders, and has made the materials available on its website. The presentation, framed as summary...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026